Download PDF
Synfacts 2010(3): 0267-0267  
DOI: 10.1055/s-0029-1219301
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag Stuttgart ˙ New York

Synthesis of ONO-4819

Contributor(s): Philip Kocienski
C. Ohta*, S.-i. Kuwabe, T. Shiraishi, I. Shinohara, H. Araki, S. Sakuyama, T. Makihara, Y. Kawanaka, S. Ohuchida, T. Seko
Ono Pharmaceutical Co. Ltd., Fukui, Japan
Further Information

Publication History

Publication Date:
18 February 2010 (online)

    Permissions and Reprints

Significance

EP4 is one of the four subtypes of the prostaglandin E2 receptor. As a selective agonist for EP4, ONO-4819 is being developed for the treatment of osteoporosis. This improved process for the synthesis of ONO-4819 (see also: T. Maruyama et al. Bioorg. Med. Chem. Lett. 2002, 10, 2103) generates fewer impurities and benefits from three crystalline intermediates.